BioStem Technologies, Inc. Allowance for Doubtful Other Receivables, Current
BioStem Technologies, Inc. (BSEM) had Allowance for Doubtful Other Receivables, Current of $9.02 million as of 2025-12-31, per its S-1 filed 2026-09-18.
Financial Statements › Notes › and Others
us-gaap:AllowanceForDoubtfulOtherReceivablesCurrent · last filed 2026-09-18
- 2025-12-31: Allowance for Doubtful Other Receivables, Current $9.02M.
- 2024-12-31: Allowance for Doubtful Other Receivables, Current $223.17K.
| Period end | Allowance for Doubtful Other Receivables, Current |
|---|---|
| 2025-12-31 | $9.02M S-1 · filed 2026-09-18 |
| 2024-12-31 | $223.17K S-1 · filed 2026-09-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |